Acute lymphoblastic leukemia (ALL) is a hematological cancer originated from the malignant transformation of a lymphoid precursor that is blocked at an immature stage of differentiation. ALL can arise in T- or B-cell precursors, hence being classified as T-ALL or B-ALL, respectively, which can be further subdivided according to specific genetic abnormalities ([@bib50]; [@bib51]).

T-ALL is characterized by the recurrent over-expression of a specific set of transcription factors, namely TLX1, TLX3, TAL1, LMO, HOXA, LYL1 and NKX family members, each defining a distinctive gene expression signature that identifies molecular subtypes in T-ALL ([@bib4]; [@bib21]; [@bib30]). Translocations leading to the activation of a small number of oncogenes occur in 25--50% of T-ALL cases. Other genetic abnormalities include frequent micro-deletions leading to the loss of tumor suppressor genes ([@bib10]; [@bib26]; [@bib29]). The events driving a full malignant phenotype in T-ALL include also over-expression of oncogenes, defects in the cell cycle control, gain of function mutations in cytokine receptors ([@bib46]) and tyrosine kinases ([@bib2]; [@bib45]), and activating mutations of *NOTCH1*([@bib1]; [@bib62]).

1. MicroRNAs and leukemia {#sec1}
=========================

MicroRNAs (miRNAs) - the most studied class of non-coding RNAs -- are small, 19--22 nt long, single stranded RNAs that provide post-transcriptional control of gene expression. In mammals, miRNAs function mostly as endogenous translational repressors of protein-coding genes through sequence-specific binding to the 3′-untranslated region (3′UTR) of a target messenger RNA ([@bib3]; [@bib37]). The differential expression of microRNAs in hematopoiesis suggested early on that their deregulation could have a role in leukemogenesis ([@bib9]). Initial reports of microRNA expression profiles revealed that miRNA gene expression signatures could be used to distinguish cancer types, including leukemia ([@bib24]; [@bib38]; [@bib43]; [@bib55]). In fact, the initial evidence for the involvement of miRNAs in cancer came from the molecular characterization of the 30 kb deletion 13q14 in human chronic lymphocytic leukemia (CLL). This genomic region harbors the *miR15* and *miR16* genes that were found to be deleted or down-regulated in the majority of CLL patients ([@bib7]). Both microRNAs from this cluster negatively regulate BCL2, inducing apoptosis in leukemic cells (reviewed in ([@bib48]).

Importantly, leukemia signatures should be framed in light of the microRNA variations that occur during normal hematological development ([@bib20]). Currently, the involvement of miRNAs in leukemogenesis is well established and different miRNAs have been identified as oncogenes or tumor suppressors in human leukemia. Moreover, microRNA expression signatures can be used not only to classify human acute lymphoblastic leukemia but also to predict prognosis, namely CNS involvement ([@bib65]), risk of relapse ([@bib65]) and relapse-free survival ([@bib27]; [@bib56]).

2. MicroRNAs and T-ALL {#sec2}
======================

The participation of miRNA genes, individually or as part of a network, has been implicated in the pathogenesis of T-ALL.

Initial studies concluded that, contrary to B-ALL subtypes ([@bib24]), hierarchical clustering and principal component analysis of the expression levels of 430 miRNAs in 50 clinical T-ALL specimens did not distinguish between the major cytogenetic groups (HOXA, TAL or LMO and TLX1 or TLX3), which differ by few miRNAs ([@bib42]). Nevertheless, in the high-risk subgroup of Early T-cell precursor ALL (ETP-ALL), the microRNAs miR-221 and miR-222 were found significantly up-regulated when compared to non-ETP-ALL cases ([@bib16]). Moreover, it has been proposed that miR-222 may, to some extent, contribute to the myeloid character of ETP-ALL by down-modulating ETS1 expression. The authors hypothesized also that the fact that ETP-ALL cases failed to respond to standard intensive chemotherapy and displayed poor prognosis in initial studies, could be due to the actions of miR-222. This is because miR-222, by significantly inhibiting proliferation and causing cell cycle arrest, might not only partially explain the stem-like character of ETP-ALL but also counteract the efficacy of standard chemotherapy directed to actively cycling cells ([@bib16]). In addition, miR-221 associates with poor prognosis: increased expression correlates significantly with lower 5-year overall survival rates ([@bib25]).

More recent publications involving more patients and deeper sequencing techniques, showed that molecular genetic subtypes of human T-ALL display also unique microRNA expression signatures ([@bib60]). Moreover, distinct molecular signatures on a transcriptomic and epigenetic level (microRNAs) can differentiate infant from childhood T-ALL ([@bib19]).

Many miRNAs have been found over-expressed in different tumors, functioning as oncogenes, and for that reason called oncomiRs ([@bib8]; [@bib28]; [@bib59]). OncomiRs generally promote tumor development by negatively inhibiting tumor suppressor genes and/or genes that control cell differentiation or apoptosis. In fact, the ablation of Dicer1 -- an essential component of the MicroRNA biogenesis machinery ([@bib11]) -- prevents the development and maintenance of Notch-driven T-ALL ([@bib31]). Deletion of Dicer promoted apoptosis in T-ALL cells which is, in part, mediated by miR-21 and its target Pdcd4 (programmed cell death 4) ([@bib31]). Notably, the most highly expressed set of miRNAs in human T-ALL was defined (miR-223, -19b, −20a, −92, -142-3p, −150, −93, −26a, −16 and miR-342) and tested in a mouse model of Notch1-induced T-ALL. The conclusion was that highly expressed miRNAs behave as oncomiRs and cooperate in regulating key tumor suppressor genes in human T-ALL, namely *PTEN*, *BIM*, *NF1*, *FBXW7*, *IKZF1* and *PHF6* ([@bib41]).

Conversely, miRNAs can act as tumor suppressors ([@bib7]; [@bib37]) by negatively regulating proto-oncogenes. For example, Li and colleagues ([@bib36]) found that down-regulation of miR-451 and miR-709 -- direct repressors of Myc -- is a key event during intracellular Notch1 (ICN1)-induced T-ALL in mice. ICN1 promotes the degradation of E2a, a transcriptional activator of miR-451 and miR-709, hence leading to the down-regulation of these miRNAs. In agreement, human T-ALL cells with NOTCH1 activating mutations have decreased miR-451 (miR-709 is not conserved in humans) and increased MYC levels. Later, Sanghvi et al. used differential expression analysis of miRNAs against normal thymocytes, analysis of anti-proliferative effects *in vitro* and tumor suppressive function *in vivo*, to identify a network of miRNAs (*miR*-*29*, *miR*-*31*, *miR*-*150*, *miR*-*155*, and *miR*-*200*) with interconnected tumor suppressive effects in T-ALL ([@bib54]). This work showed that there is a widespread mechanism of oncogene activation in T-ALL via elimination of tumor suppressor miRNA actions.

With no intension of being an exhaustive summary of all microRNAs implicated in T-ALL pathogenesis, this review will focus on some of the most studied ones ([Table 1](#tbl1){ref-type="table"}).Table 1Main microRNAs referred in this review, their role in the disease and their validated or predicted targets.Table 1microRNAExpression levelRoleTargetReferencemiR-142-3pOE in T-ALLOncomiRGRa[@bib39]miR-146b-5pDR in T-ALLTumor Supressor miR[@bib14]miR-19OE in T-ALLOncomiRBim, Pkraa1, Pten, PP2A[@bib42]miR-196bOE in HOXA T-ALL subtype\
DR in pediatric T-ALLDependent on the genetic contextERG c-Myc([@bib5]; [@bib17])miR-21OncomiR in Notch-driven T-ALLPdcd4[@bib31]miR-222OE in ETP-ALLOncomiRETS1[@bib16]miR-223OE in T-ALLOncomiRFBXW7([@bib13]; [@bib40])miR-26bDR in T-ALLTumor Supressor miRPIK3CD[@bib64]miR-30aTumor Supressor miRNOTCH1 NOTCH2[@bib47]miR-451DR in NOTCH1^mut^ T-ALLTumor Supressor miRMYC[@bib54][^1][^2]

3. The miR-17-92 microRNA cluster {#sec3}
=================================

The human polycistron encoding the miR-17-92 microRNA cluster is located at the chromosome 13q31, a genomic region that is recurrently amplified in lymphomas and other cancers (reviewed in ([@bib18])). The human miR-17−92 transcript can be processed into seven mature miRNAs (miR-17−5p, −17−3p, −18a, −19a, −20a, −19b, and miR-92). The miRNAs encoded from this cluster are highly expressed in murine lymphocytes, embryonic stem cells and precursors. The expression of theses miRNAs decreases upon maturation during lymphocyte development ([@bib63]). The genomic region encoding the miR-17-92 cluster is often amplified in human B-cell lymphomas and cooperates with up-regulated c-Myc expression to accelerate the formation of B cell lymphomas in mice ([@bib28]). Furthermore, increased expression of miR-17−92 in mouse lymphocytes results in the development of a lymphoproliferative disease and autoimmunity, causing the premature death of the mice ([@bib63]). In T-ALL, this cluster is involved in a genomic rearrangement, the translocation t(13; 14)(q32; q11) with the TCRA/D locus ([@bib42]). MiR-19, the cluster component with highest expression in T-ALL, enhances lymphocyte survival and cooperates to promote leukemogenesis in a mouse model of Notch1-induced T-ALL. In this model, miR-19 targets the pro-apoptotic protein Bim, AMP-activated kinase (Prkaa1), and the tumor suppressors Pten and PP2A, resulting in the overall activation of PI3K signaling. In this way, miR-19 directs a coordinated action to control PI3K signaling to promote lymphocyte survival and leukemogenesis ([@bib42]). The mechanisms of pri-miR-17-92 activation in T-ALL extend beyond the translocation mentioned above and remain to be fully understood. It has been proposed that NK-like homeodomain proteins could stimulate the expression of this polycistron in T-ALL ([@bib44]).

4. MiR-223 {#sec4}
==========

The miR-223, reported as a 'myeloid' gene ([@bib23]), is highly up regulated in T-ALL. It was shown to promote Notch1-driven leukemia at least in part by controlling the E3 ligase FBXW7 ([@bib41]). Moreover, miR-223 is a direct target of NOTCH in human T-ALL cells. The binding of NOTCH to miR-223 promoter region requires NF-kB activation ([@bib32]). We and others ([@bib13]; [@bib40]) have shown that TAL1 -- a major oncogenic transcription factor involved in T-ALL pathogenesis (reviewed in ([@bib12])) - binds upstream of miR-223. This binding occurs in a previously described region containing a conserved proximal genomic element with binding sites for the transcription factor C/EBPα and PU.1 ([@bib23]). MiR-223 is activated by TAL1 and follows the same pattern of expression along thymocyte development as TAL1 ([@bib49]), with high levels in progenitor cells and sharp down-regulation in more differentiated thymocyte subsets ([@bib13]). Enforced expression of miR-223 was able to partially rescue the proliferation inhibition caused by TAL1 knockdown, establishing this miRNA as a functional downstream effector of TAL1 in T-ALL cells ([@bib40]). In this study the link between TAL1 and FBXW7 down-regulation, mediated by miR-223, was firmly established as a mechanism leading to down-regulation of FBXW7 in the majority of T-ALL cases that lack gene-specific FBXW7 inactivating mutations or deletions ([@bib40]). FBXW7 targets to degradation other oncogenic proteins, such as c-MYC, MYB, cyclin E, mTOR, HIF-1 and MCL-1 ([@bib61]). The oncogene MYB, known to be involved in malignant hematopoiesis ([@bib33]), is also a direct target of TAL1 ([@bib53]). Given that FBXW7 targets MYB to degradation and that TAL1 might down-regulate FBXW7 through miR-223, it is tempting to speculate that TAL1 may regulate MYB expression levels not only transcriptionally ([@bib53]) but also at the level of protein stability through a miR-223/FBXW7 axis. In addition, the oncogenic role of miR-223 in T-ALL may extend beyond FBXW7 and involve the potential down-regulation of targets such as E2F1, FOXO1, RHOB or EPB41L3, which have been associated with induction of apoptosis and/or have tumor suppressor roles ([@bib13]).

5. MiR-142-3p {#sec5}
=============

miR-142-3p was initially identified as a specific microRNA for hematopoietic cells ([@bib9]; [@bib34]). It is highly expressed in pediatric ALL samples, particularly in T-ALL cells as compared with healthy donor T-cells ([@bib55]) and especially in T-ALL cells from patients with poor prognosis (([@bib56]) Importantly, miR-142-3p stands out as an example of the essential role that a single miRNA can play in leukemia progression, chemotherapeutic resistance and prognosis. In T-ALL, miR-142-3p was shown to promote leukemic cell growth and to induce resistance to glucocorticoid (GC) treatment ([@bib39]). In addition, ectopic expression of miR-142-3p results in the increased proliferation of T-ALL cells without affecting apoptosis. This miRNA specifically targets the cAMP/PKA pathway and glucocorticoid receptor alpha (GRa) and, importantly, T-ALL cells from patients with poor response to prednisolone are sensitized to cell death induced by dexamethasone after down-modulation of miR-142-3p ([@bib39]).

6. MiR-196b {#sec6}
===========

The role of some miRNAs in leukemia is still controversial since it may depend on the cellular context. For instance, miR-196b is highly expressed in T-ALL patient samples as compared to B-ALL ([@bib55]). In pediatric patients, miR-196b is highly co-expressed with genes from the HOXA cluster, namely in T-ALL cases characterized by the activation of HOXA genes, suggesting co-transcriptional activation ([@bib57]). The over-expression of this miRNA in mouse bone marrow cells leads to increased proliferative capacity and survival, pointing to a role in leukemogenesis ([@bib17]). In contrast, it was reported that miR-196b can down-regulate the oncogenic transcription factor ERG in adult AML and T-ALL patients. This hints on the possibility that, instead of promoting leukemogenesis, miR-196b may inhibit this process in some circumstances. In line with this, miR-196b was found down-modulated in pediatric T-ALL patients with respect to normal cells, which suggests a possible tumor suppressor function for this miRNA also in childhood T-ALL ([@bib5]). In contrast to what was previously found in B-ALL, *c-Myc* expression is not down-regulated by miR-196b in T-ALL. Interestingly, miR-196b loses its ability to down-regulate *c-Myc* expression in T-ALL as a result of mutations in the target 3′UTR of *c-Myc*, pointing again to a possible tumor suppressive role in this disease. This microRNA may therefore have a dual role in leukemia, depending on the genetic context ([@bib5]).

7. Other miRs with impact in T-ALL {#sec7}
==================================

Other microRNAs implicated in T-ALL include for instance **miR-146b-5p**, a tumor suppressor miRNA downregulated by TAL1 ([@bib15]) and involved in T-cell migration ([@bib14]; [@bib58]); the **miR-30a** - transcriptionally suppressed by MYC and a direct inhibitor of NOTCH1 and NOTCH2 expression -- mediates a regulatory circuitry that modulate the oncogenic signals of these T-ALL drivers ([@bib47]); **miR-125b** causes the malignant transformation of different hematopoietic lineages, leading to B-ALL, T-ALL, or myeloproliferative neoplasms ([@bib6]). Recently this microRNA was shown to be activated by TLX3 in the TLX3-subtype of T-ALL ([@bib52]); **miR-26b**, another tumor suppressor, is an inhibitor of the PI3K/AKT pathway via the targeting of PIK3CD. MiR-26 expression is promoted by PTEN -- another inhibitor of the pathway - by an unknown mechanism that involves the differential regulation of isoforms of the transcription factor Ikaros ([@bib64]); **miR-181a** -- encoded by the miR-181ab1 gene -- contributes to the maintenance of Notch oncogenic signals in T-ALL by diminishing Notch negative feedbacks (mediated for instance by Nrarp) and potentiating pre-TCR signals ([@bib22]). The deletion of miR-181ab1 gene has no significant impact on normal development, making miR-181a an interesting therapeutic target to inhibit oncogenic signals as alternative to the targeting of oncogenes themselves ([@bib22]).

8. Conclusion {#sec8}
=============

Since microRNAs were discovered, around 25 years ago, we have understood their biogenesis, the mechanisms how they regulate mRNA stability and protein translation and their importance in normal development and physiology. We have also started to appreciate the importance of their deregulation in the genesis and development of malignancy. Many, if not most, protein-coding transcripts are potential targets for miRNA regulation ([@bib35]). An additional layer of complexity is added by the fact that one miRNA is able to target many transcripts of genes often with related functions. Furthermore, several individual transcripts can be targeted by numerous miRNAs that are often regulated together. Integration of data from the *miRnome* with the transcriptome and proteome will be fundamental for a more comprehensive analysis of the consequences of disrupting the cellular architecture sustained by microRNAs. This obviously requires broad and large cohorts of patients and appropriate healthy tissue, which is a challenge for a rare disease like T-ALL. Nevertheless, miRNAs are not only very interesting biomarkers for various diseases, including T-ALL, but also their tissue specificity makes them attractive candidates for targeted therapy.
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[^1]: OE -- overexpressed.

[^2]: DR -- down-regulated.
